MORRIS PLAINS, N.J., April 1, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that six posters will be presented at the 2013 Annual Meeting of the American Association for Cancer Research to be held in Washington, DC, from April 6 – 10, 2013.
